(Q37056337)

18 August 2017

1 reference

title

Progress in the development of prognostic and predictive markers for gastrointestinal malignancies (English)

1 reference

18 August 2017

1

Crystal S Denlinger

1 reference

18 August 2017

Steven J Cohen

2

1 reference

18 August 2017

publication date

1 October 2007

1 reference

Current Treatment Options in Oncology

18 August 2017

published in

1 reference

18 August 2017

volume

8

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

339-351

1 reference

Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer.

18 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11864-007-0045-X

Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11864-007-0045-X

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells

21 January 2018

1 reference

12 December 2020

Experience of 1446 rectal cancer patients in Korea and analysis of prognostic factors

1 reference

12 December 2020

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

1 reference

12 December 2020

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy

1 reference

12 December 2020

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

1 reference

12 December 2020

A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer

1 reference

12 December 2020

Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels

1 reference

12 December 2020

Detection of carcinoembryonic antigen messenger RNA-expressing cells in peripheral blood 7 days after curative surgery is a novel prognostic factor in colorectal cancer.

1 reference

12 December 2020

Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract

1 reference

12 December 2020

Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.

1 reference

12 December 2020

Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.

1 reference

12 December 2020

Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.

1 reference

12 December 2020

Clinical trial designs for predictive marker validation in cancer treatment trials

1 reference

12 December 2020

Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

1 reference

12 December 2020

Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma.

1 reference

12 December 2020

Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer

1 reference

12 December 2020

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy

1 reference

12 December 2020

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

12 December 2020

High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil.

1 reference

12 December 2020

Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy

1 reference

12 December 2020

Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin.

1 reference

12 December 2020

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

12 December 2020

Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil

1 reference

12 December 2020

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

1 reference

12 December 2020

Stage II colon cancer prognosis prediction by tumor gene expression profiling

1 reference

12 December 2020

ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.

1 reference

12 December 2020

Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling.

1 reference

12 December 2020

Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

1 reference

12 December 2020

Quantification of cytokeratin 20, carcinoembryonic antigen and guanylyl cyclase C mRNA levels in lymph nodes may not predict treatment failure in colorectal cancer patients

1 reference

12 December 2020

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

12 December 2020

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer

1 reference

12 December 2020

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

1 reference

12 December 2020

Role of DNA mismatch repair defects in the pathogenesis of human cancer

1 reference

12 December 2020

Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer

1 reference

12 December 2020

Molecular determinants of cetuximab efficacy

1 reference

12 December 2020

Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.

1 reference

12 December 2020

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

1 reference

12 December 2020

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

1 reference

12 December 2020

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

1 reference

12 December 2020

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

12 December 2020

Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study

1 reference

12 December 2020

The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity

1 reference

12 December 2020

Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles.

1 reference

12 December 2020

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

1 reference

12 December 2020

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

12 December 2020

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

12 December 2020

Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie

1 reference

12 December 2020

Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients

1 reference

12 December 2020

Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil

1 reference

12 December 2020

Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer

1 reference

12 December 2020

Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q

1 reference

12 December 2020

Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients

1 reference

12 December 2020

Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response

1 reference

12 December 2020

Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells.

1 reference

12 December 2020

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

1 reference

12 December 2020

Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase

1 reference

12 December 2020

The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials

1 reference

12 December 2020

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

12 December 2020

Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement

1 reference

12 December 2020

Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma

1 reference

12 December 2020

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

12 December 2020

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

12 December 2020

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer

1 reference

12 December 2020

Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases

1 reference

12 December 2020

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

1 reference

12 December 2020

Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan

1 reference

12 December 2020

Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases

1 reference

12 December 2020

Microsatellite instability and colorectal cancer prognosis.

1 reference

12 December 2020

RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine

1 reference

12 December 2020

Molecular predictors of survival after adjuvant chemotherapy for colon cancer

1 reference

12 December 2020

Cancer statistics, 2007

1 reference

12 December 2020

Determinants of survival in patients with unresectable colorectal liver metastases

1 reference

12 December 2020

Systematic review of microsatellite instability and colorectal cancer prognosis

1 reference

12 December 2020

10.1007/S11864-007-0045-X

Identifiers

DOI

1 reference

release_rfenjq5x2raxllttheit364kwm

18 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rfenjq5x2raxllttheit364kwm

24 November 2022

mapped directly with Wikidata item

1 reference